Synta Pharmaceuticals - Competitors

Synta Pharmaceuticals Competition

Now Viewing Synta Pharmaceuticals's competition in: Biotechnology Sector

Recent Developments

Major Patent Decision Falls Genentech's Way - Genentech, one of the largest biotech companies, recently won a judgment regarding one of its most lucrative patents, Cabilly 415, which will allow the company to continue to profit from licensed technologies. The patent is for a significant process in the biotech industry that allows antibody production in several applications. The dispute was brought by MedImmune, which pays royalties to Genentech because MedImmune uses the patented technology in its products.

Economy Doesn't Slow Biotech Support - State and local governments are still courting biotech companies despite a broader US economic downturn. To attract biotech firms to Long Island's Broad Hollow Bioscience Park, New York has spent over $40 million. The State of Missouri is working with biotech firms to increase funding in support of two multimillion dollar projects in St. Louis.

Genetic Modification Explosion Continues - Following a recent increase in genetic plant modification activity, Dow AgroSciences, in partnership with biotech firm Sangamo BioSciences, has announced a new advance that may shorten development and approval times for genetically modified crops and plants. The announcement comes on the heels of a similar announcement by Monsanto that it has developed several pest-resistant seed strains. The surge in activity is due in part to increasing concerns about drought in many parts of the world and rising demand on the global food system.

Competitive Landscape

Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential products is so large, small biotechnology companies can co-exist successfully with large ones if they have expertise in a particular line of research.

Full Industry Overview For Biotechnology Sector

Biotechnology Sector Industry Forecast

from Hoover's/D&B subsidiary First Research

The output of US scientific R&D, an indicator of biotech activity, is forecast to grow at an annual compounded rate of 8.5 percent between 2007 and 2012.

Scientific R&D Growth Strong and Steady

First Research forecasts are based on INFORUM forecasts that are licensed from the Interindustry Economic Research Fund, Inc. (IERF) in College Park, MD. INFORUM's "interindustry-macro" approach to modeling the economy captures the links between industries and the aggregate economy.